Investigational drug · Phase 2
GIA632
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "GIA632"
First trial start
2025
Nov 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GIA632", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Non-segmental Vitiligo
- Cutaneous Lichen Planus
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "GIA632" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen PlanusPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07775924 · 259 participants (planned) · Start Sep 29, 2026 · Primary completion Nov 22, 2028
Drug: Placebo; GIA632 · For: Cutaneous Lichen Planus
Sites: Birmingham, Alabama; Fountain Valley, California; Hollywood, Florida · 27 sites in all
- A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07431177 · 210 participants (planned) · Start Mar 9, 2026 · Primary completion Jun 6, 2028
Drug: GIA632; Placebo · For: Non-segmental Vitiligo
Sites: Birmingham, Alabama; Fountain Valley, California; San Diego, California · 85 sites in all
- Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic DermatitisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07220577 · 34 participants · Start Nov 10, 2025 · Primary completion May 17, 2027
Drug: GIA632 · For: Atopic Dermatitis
Sites: Fremont, California; Rockville, Maryland; Hoboken, New Jersey · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.